Among the great variety of extracolonic manifestations of familial adenomatous polyposis, the most serious are desmoids and fibromatosis of the abdominal cavity. These may be a danger to the patient and a concern to the clinician. Pharmacological management of this relentless problem is favored by surgical intervention. At present, however, beneficial actions of medical therapy are not separable from undesirable side effects.
Methods
We studied the effects of 120 mg daily of raloxifene, a non-steroidal benzothiophene, on progressive desmoid tumors and mesenteric fibromatosis by evaluation of lesion size and symptoms in 13 patients with familial adenomatous polyposis, selected on the basis of intra-abdominal localization of the lesion, on refractoriness to other medical treatments, and on estrogen receptor-α expression.
Results
The patients had a significant response to raloxifene therapy, with complete remission in 8 cases and partial response in 5 cases, evaluated by regression of symptoms and tumor size. Serum biochemical parameters did not show any significant changes. Side effects were never observed.
Conclusions
Although the number of patients included in the study is limited and in spite of some limitations, the available results support that, in the evaluation of response, daily therapy with raloxifene decreases desmoid tumor and mesenteric fibromatosis size and symptoms and does not cause side effects. These findings offer a novel option in the pharmacological treatment of desmoids, leading to medical therapy of these neoplastic lesions in familial adenomatous polyposis patients.
ChruchJ.M.: Desmoid tumors in patients with familial adenomatous polyposis.Semin Colon Rectal Surg,6: 29–32, 1995.
6.
MiyakiM., KonishiM., Kikuchi-YanoshitaR., EnomotoM., TanakaK., TakahashiH., MuraokaM., MoriT., KonishiF., IwamaT.: Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patients with familial adenomatous polyposis.Cancer Res,53: 5079–5082, 1993.
7.
PalmirottaR., CuriaM.C., EspositoD.L., ValanzanoR., MesseriniL., FicariF., BrandiM.L., TonelliF., Mariani-CostantiniR., BattistaP.: Novel mutations and inactivation of both alleles of the APC gene in desmoid tumors.Hum Mol Genet,4: 1979–1981, 1995.
8.
Herrera-OrnelasL., ElsiahS., PetrelliN., MittelmanA.: Causes of death in patients with familial polyposis coli (FPC).Semin Surg Oncol,3: 109–117, 1987.
9.
VasenH.F., GriffioenG., OfferhausG.J., Den Hartog JagerF.C., Van Leeuwen-CornelisseI.S., Meera KhanP., LamersC.B., Van SlootenE.A.: The value of screening and central registration of families with familial adenomatous polyposis. A study of 82 families in The Netherlands.Dis Colon Rectum,33: 227–231, 1990.
10.
BertarioL., PresciuttiniS., SalaP., RossettiC., PietroiustiM.: Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee.Semin Surg Oncol,10: 225–234, 1994.
11.
IwamaT., MishimaY., UtsunomiyaJ.: The impact of familial adenomatous polyposis on the tumorigenesis and mortality at several organs. Its rational treatment.Ann Surg,217: 99–100, 1993.
12.
BaliskiC.R., TempleW.J., ArthurK., SchacharN.S.: Desmoid tumors: a novel approach for local control.J Surg Oncol,80: 96–99, 2002.
13.
ZloteckiR.A., ScarboroughM.T., MorrisC.G., BerreyB.H., LindD.S., EnnekingW.F., MarcusR.B.Jr.: External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis.Int J Radiat Oncol Biol Phys,54: 177–181, 2002.
14.
OkunoS.H., EdmonsonJ.H.: Combination chemotherapy for desmoid tumors.Cancer,97: 1134–1135, 2003.
15.
HeiskanenI., JarvinenH.J.: Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment.Int J Colorectal Dis,11: 157–162, 1996.
TsukadaK., ChurchJ.M., JagelmanD.G., FazioV.W., McGan-nonE., GeorgeC.R., SchroederT., LaveryI., OakleyJ.: Noncy-totoxic drug therapy for intra-abdominal desmoid tumors in patients with familial adenomatous polyposis.Dis Colon Rectum,35: 29–33, 1992.
19.
WaddellW.R., KirschW.M.: Testolactone, sulindac, warfarin, and vitamin K for unresectable desmoid tumors.Am J Surg,161: 416–421, 1991.
20.
KleinW.A., MillerH.H., AndersonM., DeCosseJ.J.: The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis.Cancer,60: 2863–2868, 1987.
21.
SeiterK., KemenyN.: Successful treatment of a desmoid tumor with doxorubicin.Cancer,71: 2242–2244, 1993.
22.
HamiltonL., BlacksteinM., BerkT., McLeodR.S., GallingerS., MadlenskyL., CohenZ.: Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases.Can J Surg,39: 247–252, 1996.
23.
PennaC., TiretE., ParcR., SfairiA., KartheuserA., HannounL., NordlingerB.: Operation and abdominal desmoid tumors in familial adenomatous polyposis.Surg Gynecol Obstet,177: 263–268, 1993.
24.
EasterD.W., HalaszN.A.: Recent trends in the management of desmoid tumors.Ann Surg,210: 765–769, 1989.
25.
WaddellW.R.: Treatment of intra-abdominal and abdominal wall desmoid tumors with drugs that affect the metabolism of cyclic 3’,5′-adenosine monophosphate.Ann Surg,181: 299–302, 1975.
PicarielloL., BrandiM.L., FormigliL., OrlandiniS.Z., DolaraP., CaderniG., RaimondiL., TonelliF.: Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms.Eur J Pharmacol,360: 105–112, 1998.
28.
KhorsandJ., KarakousisC.P.: Desmoid tumors and their management.Am J Surg,149: 215–218, 1985.
29.
KinzbrunnerB., RitterS., DomingoJ., RosenthalC.J.: Remission of rapidly growing desmoid tumors after tamoxifen therapy.Cancer,52: 2201–2204, 1983.
30.
SportielloD.J., HoogerlandD.L.: A recurrent pelvic desmoid tumor successfully treated with tamoxifen.Cancer,67: 1443–1446, 1999.
31.
ProcterH., SinghL., BaumM., BrinkleyD.: Response of multicentric desmoid tumours to tamoxifen.Br J Surg,74: 401, 1987.
32.
WilckenN., TattersallM.H.: Endocrine therapy for desmoid tumors.Cancer,68: 1384–1388, 1991.
33.
BusP.J., VerspagetH.W., Van KriekenH.J.M., de RoosA., KeizerH.J., BemelmanW.A., VasenH.F., LamersC.B., GriffioenG.: Treatment of mesenteric desmoid tumors with the anti-oe-strogenic agent toremifene: case histories and an overview of the literature.Eur J Gastroenterol Hepatol,11: 1179–1183, 1999.
DelmasP.D., BjarnasonN.H., MitlakB.H., RavouxA.C., ShahA.S., HusterW.J., DraperM., ChristiansenC.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.N Engl J Med,337: 1641–1647, 1997.
36.
EttingerB., BlackD.M., MitlakB.H., KnickerbockerR.K., NickelsenT., GenantH.K., ChristiansenC., DelmasP.D., ZanchettaJ.R., StakkestadJ., GluerC.C., KruegerK., CohenF.J., EckertS., EnsrudK.E., AvioliL.V., LipsP., CummingsS.R.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.JAMA,282: 637–645, 1999.
CohenI., RosenD.J., ShapiraJ., CordobaM., GilboaS., AltarasM.M., YigaelD., BeythY.: Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients.Gynecol Oncol,52: 185–190, 1994.
39.
KedarR.P., BourneT.H., PowlesT.J., CollinsW.P., AshleyS.E., CosgroveD.O., CampbellS.: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial.Lancet,343: 1318–1321, 1994.
40.
FisherB., CostantinoJ.P., RedmondC.K., FisherE.R., WickerhamD.L., CroninW.M.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.J Natl Cancer Inst,86: 527–537, 1994.
41.
FisherB., CostantinoJ.P., WickerhamDL, RedmondC.K., Ka-vanahM., CroninW.M., VogelV., RobidouxA., DimitrovN., AtkinsJ., DalyM., WieandS., Tan-ChiuE., FordL., WolmarkN.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst,90: 1371–1388, 1998.
42.
PicarielloL., FiorelliG., BenvenutiS., BrandiM.L., GalliG., MalentacchiC., MontaliE., BigozziU., FicariF., TonelliF.: In vitro bioeffects of the antiestrogen LY117018 on desmoid tumor and colon cancer cells.Anticancer Res,17: 2099–2104, 1997.
43.
FiorelliG., PicarielloL., MartinetiV., TonelliF., BrandiM.L.: Functional estrogen receptor b in colon cancer cells.Biochem Biophys Res Commun,261: 521–527, 1999.
44.
CummingsS.R., EckertS., KruegerK.A., GradyD., PowlesT.J., CauleyJ.A., NortonL., NickelsenT., BjarnasonN.H., MorrowM., LippmanM.E., BlackD., GlusmanJ.E., CostaA., JordanV.C.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.JAMA,281: 2189–2197, 1999.
45.
YaffeK., KruegerK., SarkarS., GradyD., Barrett-ConnorE., CoxD.A., NickelsenT.: Multiple outcomes of raloxifene evaluation investigators: cognitive function in postmenopausal women treated with raloxifene.N Engl J Med,344: 1207–1213, 2001.
46.
LimC.L., WalkerM.J., MehtaR.R., Das GuptaT.K.: Estrogen and antiestrogen binding sites in desmoid tumors.Eur J Cancer Clin Oncol,22: 583–587, 1986.
47.
TonelliF., ValanzanoR., BrandiM.L.: Pharmacologic treatment of desmoid tumors in familial adenomatous polyposis: results of an in vitro study.Surgery,115: 473–479, 1994.
48.
SerpellJ.W., Paddle-LedinekJ.E., JohnsonW.R.: Modification of growth of desmoid tumours in tissue culture by anti-oe-strogenic substances: a preliminary report.Aust N Z J Surg,66: 457–463, 1996.
49.
BlackL.J., SatoM., RowleyE.R., MageeD.E., BekeleA., WilliamsD.C., CullinanG.J., BendeleR., KauffmanR.F., BenschW.R.: Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.J Clin Invest,93: 63–69, 1994.
50.
BakerV.L., DraperM., PaulS., AllerheiligenS., GiantM., ShifrenJ., JaffeR.B.: Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles.J Clin Endocrinol Metab,83: 6–13, 1998.
VeronesiU., MaisonneuveP., CostaA., SacchiniV., MaltoniC., RobertsonC., RotmenszN., BoyleP.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.Lancet,352: 93–97, 1998.
53.
KeH.Z., QiH., CrawfordT.D.: A new selective estrogen receptor modulator (SERM), CP 336,156, preserves bone strength, decreases total serum cholesterol without causing prostate hypertrophy in a model of male osteoporosis.Bone,23: 183, 1998.
54.
BertarioL., RussoA., Sala, EboliM., GiarolaM., D'amicoF., GismondiV., VarescoL., PierottiM.A., RadiceP.: Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis.Int J Cancer95: 102–107, 2001.
